The maker of cannabis-derived medications, including Sativex and Epidiolex, recorded a net loss for the quarter of $50.1 million compared with a year-ago net loss of $69.5 million.
GW Pharma trades on the Nasdaq under the ticker symbol GWPH.
Epidiolex, Sativex maker GW Pharmaceuticals reports Q1 revenue, loss improvement
Latest Headlines
- New Mexico cannabis firm fined $142K for safety violations, might lose license
- Oklahoma medical marijuana regulators sued over seed-to-sale tracking
- Cannabis firm Tilray reduces minimum quorum after delayed investor meeting
- Idaho lawmakers shoot down anti-marijuana legalization measure
- Cannabis producer Hexo eyes US entry with CA$1.2 billion shelf prospectus
- Cannabis firm Tilray reduces minimum quorum after delayed investor meeting
- Cannabis producer Hexo eyes US entry with CA$1.2 billion shelf prospectus
- Toronto-based Flowr exits Australia, Uruguay, Spain cannabis markets
- Cannabis producer Tilray postpones shareholder vote on Aphria merger
- Organigram reports CA$66.4 million loss on falling cannabis sales
